Episalvan, an orphan drug for a condition called epidermolysis bullosa, is an EMA-approved drug for partial thickness wounds. Shortly after acquiring the therapy from German manufacturer Birken, Amryt put Episalvan into a Phase III study. Today, Amryt announced that the drug cleared the trial– across 223 patients, those who received the drug were more likely to see their wounds close within 45 days than those on placebo, a result that was statistically significant. CEO Joe Wiley called it “another significant milestone” for the company. However, the drug fell short on key secondary endpoints including how quickly the first wound healed after receiving treatment or placebo. Read more about Amryt and Episalvan here.